Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients

Xenobiotica

Volumn 39, Issue 12, 2009, Pages 931-938

  Chen, B ^a   Zhang, W ^a   Fang, J ^a   Jin, Z ^a   Li, J ^a   Yu, Z ^a   Cai, W ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cyclosporine (CsA); CYP3A5; Haplotype; Multidrug resistance gene (MDR1); P glycoprotein; Polymorphism; Renal transplant

Indexed keywords

ALANINE; CYCLOSPORIN; CYCLOSPORIN A; CYSTEINE; CYTOCHROME P450 3A5; GLYCINE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; THREONINE;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HAPLOTYPE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPLOTYPES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; YOUNG ADULT;

EID: 70849094684     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903226025     Document Type: Article

References (34)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. (2003). P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485
2. Barrett JC, Fry B, Maller J, Daly MJ. (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
3. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V. (2004). MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 78:21-25
4. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. (1998). Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66:1621-1627
5. Chen B, Fang J, Zhang Xia, Jin Z, Yu ZC, Cai WM. (2009). Detection of C1236T, G2677T/A and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J. Clin Lab Anla 23:110-116
6. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. (2003). Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95
7. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. (1992). Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Biochem Pharmacol 43:2201-2208
8. David OJ, Johnston A. (2001). Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 23: 100-114
9. Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A. (2007). Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21:252-257
10. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. (2004). The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154
11. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. (2001). Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273
12. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH. (2006). Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 33:1093-1098
13. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
14. International Neoral Renal Transplantation Study Group. (2002). Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2:148-156
15. Kahan BD, Grevel J. (1988). Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46:631-644
16. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT. (1996). Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62:599-606
17. Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery J, Russell D, Stiller C, Muirhead N, Cole E, Paul L, Zaltzman J, Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen J, Belitsky P, Parfrey P. (1996). A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 62:1744-1752
18. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG; Pharmacogenetics of Membrane Transporters Investigators. (2003). Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
20. Lindholm A, Kahan BD. (1993). Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54:205-218
21. Lindholm A, Säwe J. (1995). Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Ther Drug Monit 17:570-573
22. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. (1994). Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955
23. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. (1997). Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260
24. Marzolini C, Paus E, Buclin T, Kim RB. (2004). Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33
25. Min DI, Ellingrod VL, Marsh S, McLeod H. (2004). CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 26: 524-528
26. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. (2002). Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 postrenal transplantation and incidence of rejection in the first month. Ther Drug Monit 24:479-486
27. Nankivell BJ, Hibbins M, Chapman JR. (1994). Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 58: 989-996
28. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K. (1995). Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 17:642-654
29. Ponticelli C, Minetti L, Di Palo FQ, Vegeto A, Belli L, Corbetta G, Tarantino A, Civati G. (1988). The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 45:908-913
30. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK. (2008). Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64:1069-1084
31. Sakaeda T, Nakamura T, Okumura K. (2002). MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25:1391-1400
32. Schroeder TJ, Hariharan S, First MR. (1994). Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 26:2787-2790
33. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. (2002). Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:425-427
34. The Canadian Multicentre Transplant Study Group. (1986). A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 314:1219-1225